Navigation Links
Molecular cubes in the sunlight
Date:8/26/2008

This press release is also available in German.

Hydrogen will be one of the most important fuels of the future. It would be ideal to obtain hydrogen by splitting water instead of from petroleum. However, the electrolysis of water is a very energy intensive process, making it both expensive and unsustainable if the electricity necessary to generate it comes from the burning of fossil fuels. Photolysis, the splitting of water by light, is a highly promising alternative. A team of Australian and American researchers has now developed a catalyst that effectively catalyzes one of the necessary half reactions, the photooxidation of water. As it reports in the journal Angewandte Chemie, the core of the catalyst is a manganese-containing complex modeled after those found in photosynthetic organisms.

Electrolysis is the reverse of the process that occurs in a battery: that is electrical energy is converted to chemical energy. The electrolysis of water involves two half reactions: at the cathode, protons (positively charged hydrogen ions) are reduced to hydrogen, whereas at the anode the oxidation of water produces oxygen. The goal of the researchers is to use sunlight to get this energy-intensive process going. To make this work, the light-harvesting power of modern solar cells must be combined with effective photocatalysts for the oxidation of water and reduction of hydrogen ions into hydrogen gas.

The biggest hurdle to overcome in the photocatalytic splitting of water to date has been the lack of a robust catalyst that oxidizes water. In fact, the best known catalyst, which very effectively oxidizes water when irradiated with visible light, is a manganese-containing enzyme in the photosynthetic apparatus of living organisms. Robin Brimblecombe and Leone Spiccia at Monash University (Australia), Gerhard F. Swiegers at the Commonwealth Scientif
'/>"/>

Contact: Leone Spiccia
Leone.Spiccia@sci.monash.edu.au
61-399-054-526
Wiley-Blackwell
Source:Eurekalert  

Page: 1 2

Related biology news :

1. AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
2. Rice lab finds molecular clues to Wilson disease
3. Caltech researchers awarded $10M for molecular programming project
4. Newly discovered molecular switch helps decide cell type in early embryo development
5. Fossil and molecular evidence reveals the history of major marine biodiversity hotspots
6. MicroRNA implicated as molecular factor in alcohol tolerance
7. SNM awards $300,000 to support molecular imaging research
8. Livermore researchers use carbon nanotubes for molecular transport
9. A molecular switch turns on the flame in natures blowtorch
10. Scientists discover a molecular scaffold that guides connections between brain cells
11. Molecular clock could predict risk for developing breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecular cubes in the sunlight
Molecular cubes in the sunlight
Breaking Biology News(10 mins):Rodent smoke screen 2Superior offspring without genetic modification 2Plate-eating good: Université de Montréal professor designs edible tableware 2Labopharms response for novel trazodone formulation accepted by FDA as complete Designated as Class 2 resubmission 55334 1Labopharms response for novel trazodone formulation accepted by FDA as complete Designated as Class 2 resubmission 55334 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 1Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 2Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 3Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 4Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 5Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 6Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 7Amgen Announces Top Line Results of Trial to Reduce Cardiovascular Events With Aranesp 28R 29 Therapy 28TREAT 29 in CKD Patients With Type 2 Diabetes 4898 8ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once Daily Xibrom 28TM 29 0 09 25 4897 1ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once Daily Xibrom 28TM 29 0 09 25 4897 2ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once Daily Xibrom 28TM 29 0 09 25 4897 3